I am currently the CEO . We believe that our lead drug EPB 348 will be the first permanently effective drug for Alzheimer’s Disease > See the papers on HHVs and AD last week in Neuron. We are creating a paradigm shift concerning the role of infectious disease in AD, MS, RA, SLE and GBMPhone : 4152053796Before starting Epiphany, I was a Managing Director of RCT Bioventures and have served on the board of Imagine Pharmaceuticals, Kerberos Proximal Solutions, Catalayst Biosciences and Cylene Pharmaceuticals. In addition, I founded Exhale Pharmaceuticals-now known as Cotherix in 1999. Cotherix went public in 1999 and was recently acquired for $420million.Prior to my Biotech career, I was an academic physician at Harvard Medical School and was a founding faculty member of the Harvard Residency in Emergency Medicine.I am also currently involved in teaching innovation and translational medicine through a series of non-profit courses which I have led at Stanford, Harvard and UCSD. As a serial inventor and entrepreneur, I help academics learn about the commercialization process and about cross-disciplinary problem solving.Specialties: Health servicesMedical devicesdrug development